首页> 外文期刊>EMBO Molecular Medicine >The isolated carboxy‐terminal domain of human mitochondrial leucyl‐tRNA synthetase rescues the pathological phenotype of mitochondrial tRNA mutations in human cells
【24h】

The isolated carboxy‐terminal domain of human mitochondrial leucyl‐tRNA synthetase rescues the pathological phenotype of mitochondrial tRNA mutations in human cells

机译:人类线粒体亮氨酰tRNA合成酶的羧基末端结构域可挽救人类细胞中线粒体tRNA突变的病理表型

获取原文
       

摘要

AbstractMitochondrial (mt) diseases are multisystem disorders due to mutations in nuclear or mtDNA genes. Among the latter, more than 50% are located in transfer RNA (tRNA) genes and are responsible for a wide range of syndromes, for which no effective treatment is available at present. We show that three human mt aminoacyl-tRNA syntethases, namely leucyl-, valyl-, and isoleucyl-tRNA synthetase are able to improve both viability and bioenergetic proficiency of human transmitochondrial cybrid cells carrying pathogenic mutations in the mt-tRNAIle gene. Importantly, we further demonstrate that the carboxy-terminal domain of human mt leucyl-tRNA synthetase is both necessary and sufficient to improve the pathologic phenotype associated either with these “mild” mutations or with the “severe” m.3243AG mutation in the mt-tRNALeu(UUR) gene. Furthermore, we provide evidence that this small, non-catalytic domain is able to directly and specifically interact in vitro with human mt-tRNALeu(UUR) with high affinity and stability and, with lower affinity, with mt-tRNAIle. Taken together, our results sustain the hypothesis that the carboxy-terminal domain of human mt leucyl-tRNA synthetase can be used to correct mt dysfunctions caused by mt-tRNA mutations.SynopsisNon-cognate mitochondrial aminoacyl-tRNA syntethases improve viability and bionergetic proficiency of human cells with pathogenic mutations in the mt-tRNAIle gene. The isolated carboxy-terminal domain of human mt-leucyl tRNA synthetase improves the pathologic phenotype.Mitochondrial aminoacyl-tRNA syntethases (mt-aaRSs) can rescue the pathologic phenotype of human cells carrying mutations, both in cognate and non-cognate mitochondrial tRNAs.The carboxy-terminal domain of mt-leucyl syntethase (mt-LeuRS Cterm) is sufficient to exert the rescuing effect, even more efficiently than the whole enzyme.In line with its rescuing effect, mt-LeuRS Cterm is imported within mitochondria, even in absence of a canonical mt import sequence.
机译:摘要线粒体(mt)疾病是由于核或mtDNA基因突变引起的多系统疾病。在后者中,超过50%位于转移RNA(tRNA)基因中,并导致多种综合征,目前尚无有效的治疗方法。我们显示了三种人类mt氨酰基tRNA合成酶,即亮氨酰,valyl和异亮氨酰tRNA合成酶能够提高在mt-tRNA中携带致病突变的人线粒体杂种细胞的生存能力和生物能水平。 / sup>基因。重要的是,我们进一步证明了人mt亮氨酰-tRNA合成酶的羧基末端结构域对于改善与这些“轻度”突变或与这些“轻度”突变或“重度” m.3243A> G突变相关的病理学表型都是必要和充分的。 mt-tRNA L eu(UUR)基因。此外,我们提供的证据表明,这个小的非催化结构域能够在体外与人mt-tRNA Leu(UUR)直接且特异性地相互作用,并具有高亲和力和稳定性,并且在较低亲和力下与mt-tRNA Ile 。综上所述,我们的研究结果支持了以下假设:人mt亮氨酰tRNA合成酶的羧基末端结构域可用于纠正由mt-tRNA突变引起的mt功能障碍提要非同源线粒体氨酰基tRNA合成酶可提高人类的生存能力和生物能。 mt-tRNAIle基因中具有致病性突变的细胞。分离的人mt-亮氨酰tRNA合成酶的羧基末端结构域改善了病理表型。线粒体氨酰基-tRNA合成酶(mt-aaRSs)可以挽救具有突变的同源和非同源线粒体tRNA中携带突变的人类细胞的病理表型。 mt-亮氨酰合酶的羧基末端结构域(mt-LeuRS Cterm)足以发挥抢救作用,甚至比整个酶更有效。规范的mt导入序列。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号